Article
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2022
Zacharakis Nikolaos, Huq Lutfi M, Seitter Samantha J, Kim Sanghyun P, Gartner Jared J, Sindiri Sivasish, Hill Victoria K, Li Yong F, Paria Biman C, Ray Satyajit, Gasmi Billel, Lee Chyi-Chia, Prickett Todd D, Parkhurst Maria R, Robbins Paul F, Langhan Michelle M, Shelton Thomas E, Parikh Anup Y, Levi Shoshana T, Hernandez Jonathan M, Hoang Chuong D, Sherry Richard M, Yang James C, Feldman Steven A, Goff Stephanie L, Rosenberg Steven A
Abstract excerpt
PURPOSE: Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in breast cancer and explores the therapeutic efficacy in a pilot trial of mutation-reactive tumor-infiltrating lymphocytes (TILs) in patients with metastatic disease. PATIENTS AND METHODS: Forty-two patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.